ArticleBMC gastroenterology2025
Burden of gastrointestinal cancers in Asia, 1990-2019.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Regional and national burden of six major digestive cancers in Asia, 1990-2023: An analysis of the GBD Study 2023.iScience · 2026Article
- A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers.Oncology research · 2026Review
- The global cancer crisis: a review of growing burden, deepening inequality and initiatives for prevention and early detection.Ecancermedicalscience · 2026Review
- Article
- Research trends and visualization analysis of autoimmune disease-related liver cancer from 2004 to 2024: a bibliometric study.Discover oncology · 2025Article
- Global burden of early-onset gallbladder and biliary tract cancer from 1990 to 2021.BMC gastroenterology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesGastrointestinal (GI) cancers are a major cause of morbidity and mortality worldwide. However, there has been no comprehensive assessment of GI cancers in Asia. STUDY
designThis was an epidemiological study.
methodsThe study calculated the incidence and deaths of six common GI cancers in Asia between 1990 and 2019 using data from the Global Burden of Disease study. The data are presented by sex, age, year, location, and risk factors, and are shown as counts and rates.
resultsIn 2019, the age-standardized incidence rates (ASIR) for colorectal, esophageal, gallbladder and biliary tract (GBTC), liver, pancreatic, and stomach cancers were 23.88, 8.24, 2.77, 7.97, 5.41, and 19.77, respectively. The age-standardized death rates (ASDR) for colorectal, esophageal, GBTC, liver, pancreatic, and stomach cancers were 12.49, 7.73, 2.53, 7.22, 5.47, and 14.67, respectively. From 1990 to 2019, there was an increasing trend in incidence and deaths for esophageal, liver, and stomach cancer, while a decreasing trend was observed in colorectal, GBTC, and pancreatic cancer. The burden of GI cancer increased successively in older generations and was higher in males than in females. Furthermore, this burden varied significantly across Asian subregions and countries. Dietary risks, smoking, alcohol use, and high BMI contribute to GI cancer mortality.
conclusionsGI cancers continue to be the primary contributor to the tumor burden in Asia, with increasing absolute numbers but varying age-standardized measures over the past three decades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.